J 2023

RETRO-POPE: A Retrospective, Multicenter, Real-World Study of All-Cause Mortality in COPD

KOBLIZEK, Vladimir, Branislava MILENKOVIC, Michal SVOBODA, Jana KOCIANOVA, Stanislav HOLUB et. al.

Základní údaje

Originální název

RETRO-POPE: A Retrospective, Multicenter, Real-World Study of All-Cause Mortality in COPD

Autoři

KOBLIZEK, Vladimir (203 Česká republika), Branislava MILENKOVIC (203 Česká republika), Michal SVOBODA (203 Česká republika, domácí), Jana KOCIANOVA (203 Česká republika), Stanislav HOLUB (203 Česká republika), Vladimir ZINDR (203 Česká republika), Miroslav ILIC (203 Česká republika), Jelena JANKOVIC (203 Česká republika), Vojislav CUPURDIJA, Jiří JARKOVSKÝ (203 Česká republika, domácí), Boris POPOV a Arschang VALIPOUR

Vydání

International Journal of chronic obstructive pulmonary disease, Albany, Dove Medical Press Ltd. 2023, 1178-2005

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30203 Respiratory systems

Stát vydavatele

Nový Zéland

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 2.800 v roce 2022

Kód RIV

RIV/00216224:14110/23:00133349

Organizační jednotka

Lékařská fakulta

UT WoS

001109137500001

Klíčová slova anglicky

COPD; survival; mortality; Central and Eastern Europe; respiratory; clinical phenotype; cluster

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 31. 1. 2024 12:38, Mgr. Tereza Miškechová

Anotace

V originále

Purpose: The Phenotypes of COPD in Central and Eastern Europe (POPE) study assessed the prevalence and clinical characteristics of four clinical COPD phenotypes, but not mortality. This retrospective analysis of the POPE study (RETRO-POPE) investigated the relationship between all-cause mortality and patient characteristics using two grouping methods: clinical phenotyping (as in POPE) and Burgel clustering, to better identify high-risk patients.Patients and Methods: The two largest POPE study patient cohorts (Czech Republic and Serbia) were categorized into one of four clinical phenotypes (acute exacerbators [with/without chronic bronchitis], non-exacerbators, asthma-COPD overlap), and one of five Burgel clusters based on comorbidities, lung function, age, body mass index (BMI) and dyspnea (very severe comorbid, very severe respiratory, moderate-to-severe respiratory, moderate-to-severe comorbid/obese, and mild respiratory). Patients were followed-up for approximately 7 years for survival status.Results: Overall, 801 of 1,003 screened patients had sufficient data for analysis. Of these, 440 patients (54.9%) were alive and 361 (45.1%) had died at the end of follow-up. Analysis of survival by clinical phenotype showed no significant differences between the phenotypes (P=0.211). However, Burgel clustering demonstrated significant differences in survival between clusters (P<0.001), with patients in the "very severe comorbid" and "very severe respiratory" clusters most likely to die. Overall survival was not significantly different between Serbia and the Czech Republic after adjustment for age, BMI, comorbidities and forced expiratory volume in 1 second (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.65-0.99; P=0.036 [unadjusted]; HR 0.88, 95% CI 0.7-1.1; P=0.257 [adjusted]). The most common causes of death were respiratory-related (36.8%), followed by cardiovascular (25.2%) then neoplasm (15.2%).Conclusion: Patient clusters based on comorbidities, lung function, age, BMI and dyspnea were more likely to show differences in COPD mortality risk than phenotypes defined by exacerbation history and presence/absence of chronic bronchitis and/or asthmatic features.